A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Conditions

• Gastrointestinal Neoplasms

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• IDRX-42 — DRUG
  IDRX-42 will be administered.
• Sunitinib — DRUG
  Sunitinib will be administered.

Study Details

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.

Key Dates

Start date

Dec 3, 2025

Status verified

May 2026

Primary completion

May 30, 2028

Completion

Nov 29, 2030

Study Design

Enrollment

450 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: IDRX-42 (GSK6042981)
• Active Comparator: Sunitinib

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: Up to approximately 130 weeks ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (35)

Find similar trials in Phoenix, AZ

Related Studies

• Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions
  Recruiting · California Pacific Medical Center Research Institute · San Francisco, California
• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
  Recruiting · Cedars-Sinai Medical Center · Los Angeles, California
• First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
  PHASE1 · Recruiting · IDRX, Inc., a wholly owned subsidiary of GSK, LLC · Miami, Florida
• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
  PHASE1 · Recruiting · Janssen Research & Development, LLC · Aurora, Colorado